Publikasi Scopus 2024 per tanggal 29 Februari 2024 (130 artikel)

Dewangga R.; Winston K.; Ilhami L.G.; Indriani S.; Siddiq T.; Adiarto S.
Dewangga, Raditya (57414442400); Winston, Kevin (57224165400); Ilhami, Lazuardi Gayu (58828100100); Indriani, Suci (57213831064); Siddiq, Taofan (57206239827); Adiarto, Suko (8603606800)
57414442400; 57224165400; 58828100100; 57213831064; 57206239827; 8603606800
Association of metformin use with abdominal aortic aneurysm: A systematic review and meta-analysis
2024
Asian Cardiovascular and Thoracic Annals
0
Gunung Jati General Hospital, Cirebon, Indonesia; Bhakti Medicare Hospital, Sukabumi, Indonesia; Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia/Harapan Kita National Cardiovascular Center, Jakarta, Indonesia
Dewangga R., Gunung Jati General Hospital, Cirebon, Indonesia; Winston K., Bhakti Medicare Hospital, Sukabumi, Indonesia; Ilhami L.G., Bhakti Medicare Hospital, Sukabumi, Indonesia; Indriani S., Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia/Harapan Kita National Cardiovascular Center, Jakarta, Indonesia; Siddiq T., Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia/Harapan Kita National Cardiovascular Center, Jakarta, Indonesia; Adiarto S., Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia/Harapan Kita National Cardiovascular Center, Jakarta, Indonesia
Background: Abdominal aortic aneurysm (AAA) is a cardiovascular disease characterized by a high mortality rate when ruptured. Some studies suggest a potential inverse correlation between AAA and diabetes patients, especially those undergoing metformin treatment. However, this relationship remains unclear. This paper offers a systematic review and meta-analysis with the objective of clarifying the influence of metformin on AAA. Methods: A search for relevant articles was performed across multiple databases including PubMed, ScienceDirect, Cochrane and Scopus. The focus was on studies that examined the comparative effects of metformin and non-metformin treatments on AAA patients. Data from appropriate studies were consolidated to estimate the effects. Our study encompassed 11 articles, comprising 13 cohorts that compared metformin (n = 32,250) with a control group (n = 116,339). Results: The random effects meta-analysis revealed that metformin was associated with a slower growth rate (weighted mean difference (WMD) −0.86 mm; 95% CI: −1.21 to −0.52; p < 0.01; I2: 81.4%) and fewer AAA-related events (OR: 0.54; 95% CI: 0.34 to 0.86; p = 0.01; I2: 60.9%). The findings suggest that metformin may be linked to a reduced risk of aortic aneurysm. A meta-regression analysis indicated that the association between metformin and AAA growth was significantly influenced by male gender (p = 0.027), but not by age (p = 0.801), hypertension (p = 0.256), DM (p = 0.689), smoking history (p = 0.786), use of lipid-lowering agents (p = 0.715), or baseline diameter (p = 0.291). Conclusion: These results hint at a potential role for metformin in limiting annual AAA growth, AAA-related events, and the risk of AAA. © The Author(s) 2024.
Abdominal aortic aneurysm; meta-analysis; metformin; pharmacotherapy
SAGE Publications Inc.
02184923
38239055
Review
Q3
243
17130